MoonLake Immunotherapeutics financial data

Symbol
MLTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
Dorfstrasse 29, Zug, Switzerland
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
Helix Acquisition Corp (to 3/31/2022)
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.08K % +93.3%
Debt-to-equity 2.53 % -45.2%
Return On Equity -10.5 % +54.7%
Return On Assets -10.3 % +53.9%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 52.7M shares
Entity Public Float 1.12B USD +3221%
Common Stock, Value, Issued 385 USD
Weighted Average Number of Shares Outstanding, Basic 62.9M shares +43.8%
Weighted Average Number of Shares Outstanding, Diluted 62.9M shares +43.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 52.4M USD +44.2%
General and Administrative Expense 26M USD +22.4%
Operating Income (Loss) -78.4M USD -36.2%
Nonoperating Income (Expense) 17.7K USD -56.4%
Income Tax Expense (Benefit) 222K USD +443%
Net Income (Loss) Attributable to Parent -54.8M USD -33.3%
Earnings Per Share, Basic -0.88 USD/shares -165%
Earnings Per Share, Diluted -0.88 USD/shares -165%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 343M USD -31.7%
Assets, Current 537M USD +6.03%
Property, Plant and Equipment, Net 482K USD +1025%
Operating Lease, Right-of-Use Asset 3.38M USD +1502%
Assets 545M USD +7.55%
Employee-related Liabilities, Current 1.96M USD +117%
Accrued Liabilities, Current 5.8M USD +9563%
Liabilities, Current 12.3M USD +72.1%
Operating Lease, Liability, Noncurrent 2.02M USD +3714%
Liabilities 14.8M USD +97.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3.26M USD +9173%
Retained Earnings (Accumulated Deficit) -155M USD -54.9%
Stockholders' Equity Attributable to Parent 521M USD +6.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 530M USD +6.2%
Liabilities and Equity 545M USD +7.55%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.9M USD -65.6%
Net Cash Provided by (Used in) Financing Activities 51M USD
Net Cash Provided by (Used in) Investing Activities -28.8M USD -247%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7.27M USD -31.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 343M USD -31.7%
Deferred Tax Assets, Valuation Allowance 11.3M USD -3.9%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure 0%
Deferred Tax Assets, Gross 11.3M USD -3.42%
Operating Lease, Liability 3.34M USD +1483%
Depreciation 22.8K USD +593%
Payments to Acquire Property, Plant, and Equipment 212K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -52.1M USD -26.3%
Lessee, Operating Lease, Liability, to be Paid 3.55M USD +1572%
Operating Lease, Liability, Current 1.32M USD +735%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.13M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.45M USD +989%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 207K USD +17448%
Lessee, Operating Lease, Liability, to be Paid, Year Three 92.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.72M USD -6.86%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 92.7K USD
Operating Lease, Payments 364K USD +838%
Additional Paid in Capital 672M USD +14%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 6.54M USD -29.4%
Operating Leases, Future Minimum Payments Due 300K USD
Interest Expense 657 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%